KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in CashDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Cash from Investing Activities (2016 - 2025)

West Pharmaceutical Services' Cash from Investing Activities history spans 17 years, with the latest figure at -$76.1 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities rose 27.39% year-over-year to -$76.1 million; the TTM value through Dec 2025 reached -$285.9 million, up 24.5%, while the annual FY2025 figure was -$285.9 million, 24.5% up from the prior year.
  • Cash from Investing Activities for Q4 2025 was -$76.1 million at West Pharmaceutical Services, down from -$63.3 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at -$54.5 million in Q1 2021 and bottomed at -$108.8 million in Q4 2023.
  • The 5-year median for Cash from Investing Activities is -$76.8 million (2021), against an average of -$78.7 million.
  • The largest annual shift saw Cash from Investing Activities tumbled 70.85% in 2021 before it grew 27.39% in 2025.
  • A 5-year view of Cash from Investing Activities shows it stood at -$77.4 million in 2021, then dropped by 22.48% to -$94.8 million in 2022, then dropped by 14.77% to -$108.8 million in 2023, then rose by 3.68% to -$104.8 million in 2024, then rose by 27.39% to -$76.1 million in 2025.
  • Per Business Quant, the three most recent readings for WST's Cash from Investing Activities are -$76.1 million (Q4 2025), -$63.3 million (Q3 2025), and -$75.2 million (Q2 2025).